Deepak Poudyal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deepak Poudyal has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexander A. Chumanevich
Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA
1 shared publication - Anthony J. Windust
Department of Biological and Biomedical Sciences Julius L. Chambers Biomedical/Biotechnology Research Institute (BBRI) North Carolina Central University 28081 Kannapolis NC USA
1 shared publication - Anusha Chaparala
College of Pharmacy University of South Carolina 29208 Columbia SC USA
1 shared publication - Douglas L. Pittman
Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA.
1 shared publication - Erin W. Howard
Julius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, 500 Laureate Way, NRI 4301, Kannapolis, North Carolina, 28081, USA
1 shared publication - Hossam Tashkandi
College of Pharmacy University of South Carolina 29208 Columbia SC USA
1 shared publication
Latest Publications
- Open Access
- 19 March 2018
- Published by MDPI AG in Preprints.org
Panaxynol, a Bioactive Component of American Ginseng, Targets Macrophages and Suppresses Colitis in Mice
Ulcerative colitis has a significant impact on the quality of life for the patients, and can substantially increase the risk of colon cancer in patients suffering long-term. Conventional treatments provide only modest relief paired with a high risk of side effects, while complementary and alternative medicines can offer safe and effective options. Over the past decade, we have shown that American ginseng has anti-oxidant and anti-inflammatory properties that can suppress mouse colitis and prevent colitis associated colon cancer. With the goal of isolating a single active compound, we further fractionated the hexane fraction, and found the most abundant molecule in this fraction was the polyacetylene, Panaxynol. After isolating and characterizing Panaxynol, we tested the efficacy of Panaxynol in the treatment and prevention of colitis in mice and studied the mechanism of action. We demonstrate here that Panaxynol effectively treats colitis in a Dextran Sulfate Sodium mouse model by targeting macrophages for DNA damage and apoptosis. Positive outcomes from this study could take American ginseng one-step further towards becoming a conventional drug for the treatment of colitis, and possibility exploring other autoimmune diseases associated with macrophage dysfunction.
- 19 March 2018
- Published by MDPI AG in Preprints.org
Open AccessPanaxynol, a Bioactive Component of American Ginseng, Targets Macrophages and Suppresses Colitis in Mice
Ulcerative colitis has a significant impact on the quality of life for the patients, and can substantially increase the risk of colon cancer in patients suffering long-term. Conventional treatments provide only modest relief paired with a high risk of side effects, while complementary and alternative medicines can offer safe and effective options. Over the past decade, we have shown that American ginseng has anti-oxidant and anti-inflammatory properties that can suppress mouse colitis and prevent colitis associated colon cancer. With the goal of isolating a single active compound, we further fractionated the hexane fraction, and found the most abundant molecule in this fraction was the polyacetylene, Panaxynol. After isolating and characterizing Panaxynol, we tested the efficacy of Panaxynol in the treatment and prevention of colitis in mice and studied the mechanism of action. We demonstrate here that Panaxynol effectively treats colitis in a Dextran Sulfate Sodium mouse model by targeting macrophages for DNA damage and apoptosis. Positive outcomes from this study could take American ginseng one-step further towards becoming a conventional drug for the treatment of colitis, and possibility exploring other autoimmune diseases associated with macrophage dysfunction.